The Centers for Medicare & Medicaid Services (CMS) announced today that final calendar year 2015 Medicare Advantage (MA) encounter data is now available to researchers under a data use agreement.
CMS and FDA are both working to accelerate innovation in the biosimilars market – CMS has taken action to do so by providing biosimilars with separate payment codes and by lowering the amount of cost sharing that low-income beneficiaries pay for biosimilars.
CMS is announcing the Medicare Advantage Qualifying Payment Arrangement Incentive (MAQI) Demonstration. The MAQI Demonstration will be tested under the authority of Section 402 of the Social Security Amendments of 1967 (as amended).
Proposed changes to the Medicare Physician Fee Schedule and Quality Payment Program would streamline clinician billing and expand access to high-quality care.
On July 12, 2018, CMS issued a proposed rule that includes proposals to update payment policies, payment rates, and quality provisions for services furnished under the Medicare Physician Fee Schedule (PFS) on or after January 1, 2019.
President Trump’s bold leadership to lower drug prices is being heard across the nation. At CMS, we will continue to increase competition, strengthen negotiations, and lower costs for Medicare and Medicaid beneficiaries.
CMS Proposed Updates to Policies and Payment Rates for the End-Stage Renal Disease Prospective Payment System, the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Competitive Bidding Program; DMEPOS Fee Schedule Amounts, Quality Incentive Program; and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS-1691-P).